Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

Back to Search
Print
Bookmark Trial

NCT01200407

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Lorma Medical Center
San Fernando City, La Union, 2500, Philippines
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Filipino hypertensive subjects ages 18-65 years old whether naive or currently taking any other anti-hypertensive or those on monotherapy using CCBs or ARBs whom they want to shift on a fixed dose combination drug

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with contraindications to any of the component of the fixed drug (amlodipine
or olmesartan medoxomil) or with malignant or secondary hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

HypertensionAmlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients NCT01200407
  1. San Fernando City, La Union
  2. Taclobo, Dumaguete City, Negros Oriental
  3. Albay,
  4. Angono,
  5. Baguio City,
  6. Baguio,
  7. Bulacan,
  8. Calamba,
  9. Cavite,
  10. Cebu City,
  11. Cebu,
  12. Dagupan,
  13. Davao City,
  14. Davao,
  15. Eastwood,
  16. Iloilo City,
  17. Iloilo,
  18. Isabela,
  19. Kalibo Aklan,
  20. Laguna,
  21. Laoag,
  22. Lingayen, Pangasinan,
  23. Makati City,
  24. Makati City,
  25. Makati,
  26. Mandaluyong,
  27. Manila,
  28. Manila,
  29. Manila,
  30. Manila,
  31. Manila,
  32. Manila,
  33. Marikina City,
  34. Marikina,
  35. Metro Manila,
  36. Muntinlupa,
  37. Nueva Vizcaya,
  38. Olongapo,
  39. Pampanga,
  40. Paranaque,
  41. Parañaque,
  42. Pasay,
  43. Pasig City,
  44. Pasig Ciy,
  45. Pasig,
  46. Pasig,
  47. Puerto Princesa,
  48. Quezon City,
  49. Quezon CIty,
  50. Rizal,
  51. San Juan,
  52. Tacloban,
  53. Taguig,
  54. Tarlac,
  55. Tugegarao,
  56. Tuguegarao City,
  57. Tuguegarao City,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionA Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents NCT00389519
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Beverly Hills, California
  4. Los Angeles, California
  5. Orange, California
  6. Cocoa Beach, Florida
  7. Lakeland, Florida
  8. Atlanta, Georgia
  9. Augusta, Georgia
  10. Honolulu, Hawaii
  11. Park Ridge, Illinois
  12. Tinley Park, Illinois
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bridgeton, Missouri
  16. Las Vegas, Nevada
  17. Las Vegas, Nevada
  18. Toms River, New Jersey
  19. Syracuse, New York
  20. Williamsville, New York
  21. Cary, North Carolina
  22. Chapel Hill, North Carolina
  23. Durham, North Carolina
  24. Sylva, North Carolina
  25. Cincinnati, Ohio
  26. Columbus, Ohio
  27. Norman, Oklahoma
  28. Tulsa, Oklahoma
  29. Portland, Oregon
  30. Portland, Oregon
  31. Philadelphia, Pennsylvania
  32. Kingsport, Tennessee
  33. Memphis, Tennessee
  34. Beaumont, Texas
  35. Houston, Texas
  36. Salt Lake City, Utah
  37. Charlottesville, Virginia
  38. Midlothian, Virginia
  39. Norfolk, Virginia
  40. Buenos Aires,
  41. Buenos Aires,
  42. Buenos Aires,
  43. Buenos Aires,
  44. San Juan,
  45. Tucomán,
  46. Santiago,
  47. Santiago,
  48. Santiago,
  49. Vina del Mar,
  50. Barranquilla,
  51. Bogotá,
  52. Bogotá,
  53. Bogotá,
  54. Medellin,
  55. Medellin,
  56. Medellín,
  57. Ahmedabad,
  58. Ahmedabad,
  59. Bangalore,
  60. Chennai,
  61. Delhi,
  62. Delhi,
  63. Delhi,
  64. Hyderabaad,
  65. Hyderabaad,
  66. Ludhiana,
  67. Mumbai,
  68. Pune,
  69. Trivandrum,
  70. Gdansk,
  71. Katowice,
  72. Lodz,
  73. Lodz,
  74. Poznan,
  75. Szczecin,
  76. Szczecin,
  77. Torun,
  78. Warszawa,
  79. Wroclaw,
  80. Benoni,
  81. Johannesburg,
  82. Port Elizabeth,
  83. Potchefstroom,
  84. Pretoria,
  85. Pretoria,
  86. Pretoria,
  87. Pretoria,
  88. Sandton,
  89. Istanbul,
  90. Istanbul,
  91. Izmir,
  92. Samsun,
  93. Dnepropetrovsk,
  94. Kharkov,
  95. Kiev,
  96. Kyiv,
  97. Lviv,
  98. Odessa,
  99. Simferopol,
  100. Uzhorod,
  101. Vinnitsa,
ALL GENDERS
6 Years+
years
MULTIPLE SITES
HypertensionA Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient NCT00415623
  1. Kasuya-gun, Fujuoka
  2. Chikushino, Fukuoka
  3. Kitakyushu, Fukuoka
  4. Koga, Fukuoka
  5. Sapporo, Hokkaidou
  6. Sapporo, Hokkaido
  7. Yokohama, Kanagawa
  8. Iruma, Saitama
  9. Koshigaya, Saitama
  10. Adachi-ku, Tokyo
  11. Edogawa-ku, Tokyo
  12. Meguro-ku, Tokyo
  13. Setagaya-ku, Tokyo
  14. Sumida, Tokyo
  15. Fukuoka,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
HypertensionTreatment of Pediatric Hypertension With Altace Trial NCT00044265
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Augusta, Georgia
  6. Honolulu, Hawaii
  7. Park Ridge, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Baltimore, Maryland
  11. Detroit, Michigan
  12. Kansas City, Missouri
  13. St. Louis, Missouri
  14. Bronx, New York
  15. Great Neck, New York
  16. Cincinnati, Ohio
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Columbus, Ohio
  20. Portland, Oregon
  21. Hershey, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Philadelphia, Pennsylvania
  24. Pittsburgh, Pennsylvania
  25. Memphis, Tennessee
  26. Nashville, Tennessee
  27. Houston, Texas
  28. Houston, Texas
  29. Charlottesville, Virginia
  30. Madison, Wisconsin
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
Official Title An Open Label, Non-interventional Study Of The Safety, Tolerability, And Efficacy Of Amlodipine And Olmesartan Medoxomil (Normetec) In Filipino Patients With Hypertension: A Post Marketing Surveillance Study
Brief Summary The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Filipino Hypertensive patients ages 18-65 years old
Condition Hypertension
Intervention Drug: Amlodipine + Olmesartan medoxomil
start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
Study Groups/Cohorts Filipino Hypertensive patients
Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
Intervention: Drug: Amlodipine + Olmesartan medoxomil
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Terminated
Actual Enrollment
 (submitted: March 17, 2016)		615
Original Estimated Enrollment
 (submitted: September 10, 2010)		3000
Actual Study Completion Date January 2014
Actual Primary Completion Date January 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Filipino hypertensive subjects ages 18-65 years old whether naive or currently taking any other anti-hypertensive or those on monotherapy using CCBs or ARBs whom they want to shift on a fixed dose combination drug

Exclusion Criteria:

  • Patients with contraindications to any of the component of the fixed drug (amlodipine or olmesartan medoxomil) or with malignant or secondary hypertension
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Philippines
Removed Location Countries  
 
Administrative Information
NCT Number NCT01200407
Other Study ID Numbers B1581001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2016